Publications

Maggie Dong, Ph.D., Avril Gouault-Laliberté, M.Sc., Dany Hallé, M.Sc., Carla Létourneau, CMA, Catherine Beauchemin, PhD

Market Access Challenges for Innovative Medications in Women’s Health in Canada: Overview of the Past 20 Years

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) (pp HPR6) · May 2025 · Montreal, Canada (In-Person Conference)

Catherine Beauchemin, PhD, Jean Lachaine, PhD, Juliette Garneau, M.Sc., Jean-Eric Tarride, PhD

The Impact of CDA-AMC Sequential Analysis on Decision-Making in Oncology

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) (pp HTA26) · May 2025 · Montreal, Canada (In-Person Conference)

Roger McIntyre, MD, Professor, Kobina Quansah, MSc, Aysegul Erman, PhD., Sarah Jane Harrison, PhD., Cloe Esposito, PhD., Avril Gouault-Laliberté, M.Sc., Claudia Theriault, B.Sc., Catherine Beauchemin, PhD

A Key Opinion Leader Survey of Major Depressive Disorder (MDD) with Anhedonia in Canada on Frequency, Management, and Burden of MDD With Prominent Anhedonia

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) (pp CO108) · May 2025 · Montreal, Canada (In-Person Conference)

Kimberly Guinan, MSc, Julie Patenaude, MSc, Subra Seshadri, BSc, Rodgoun Attarian, PhD, Jean Lachaine, PhD

Ferric Derisomaltose for the Treatment of Iron Deficiency Anemia: A Real-World Evidence Study

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) (pp EE300) · May 2025 · Montreal, Canada (In-Person Conference)

Kimberly Guinan, MSc., Monika Ham, MSc., Harpreet Singh, MSc., Nancy Paul Roc, MSc, Hardeek Patel, MD, Peter Anglin, MD, Christopher Lemieux, MD, Beenish Manzoor, MPH, PhD, Stephane Barakat, PhD, Jean Lachaine, PhD

Healthcare Resource Utilization in the Management of Patients with Relapse/Refractory Mantle Cell Lymphoma in Canada

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) (pp EE355) · May 2025 · Montreal, Canada (In-Person Conference)

Patenaude J, Gouault Laliberté A, Beauchemin C, Lachaine J

Real-World Impact of Migraine on Canadians’ Productivity: A Pharmacy-Based Study

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) · November 2023 · Copenhagen, Denmark

(PCR175),

Ham M, Pelletier M, Guinan K, Gosselin A, Paul Roc N, Barakat S, Beauchemin C

The Impact of Phase 2 Clinical Trials on Reimbursement Recommendations in Oncology by Canadian Health Technology Assessment Agencies

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) · November 2023 · Copenhagen, Denmark

(HTA155),

Desjardins O, Jack C, Netchiporouk E, Veillette H, Baribeau V, Préfontaine D, Labelle M, Lachaine J

Real-World, Longitudinal, Retrospective Study of Healthcare Resource Utilization of Patients With Atopic Dermatitis Under the Public Health Insurance Plan of Quebec, Canada

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) · November 2023 · Copenhagen, Denmark

(EE257),

Baribeau V, Mohammed S, Awan A, Parison D, Lachaine J

Drug Utilization, Adherence, and Persistence in Parkinson’s Disease Patients in a Real-World Setting in Quebec, Canada

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) · November 2023 · Copenhagen, Denmark

(P26),

Baribeau V, Mohammed S, Awan A, Parison D, Lachaine J

Health Care Resource Utilization and Cost in Parkinson’s Disease Patients in a Real-World Setting in Quebec, Canada

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) · November 2023 · Copenhagen, Denmark

(EE44),

Lachaine J, Wong G, Baribeau V, Kalia S, Brisebois J, Ringuet J

Retrospective Database Analysis of Healthcare Resource Utilization and Costs in Patients With Vitiligo in Quebec, Canada

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) · November 2023 · Copenhagen, Denmark

(EE410),

Patenaude J, Gouault Laliberté A, Beauchemin C, Lachaine J

An Innovative Approach to Generate Patient-Centered Evidence in a Real-World Evidence Setting

Canadian Association for Population Therapeutics (CAPT) · October 2023 · Toronto, Canada

Harasymowycz P, Saheb H, Matougui K, Beauchemin C, Royer C, Shah-Manek B

Adherence and Persistence to Glaucoma Topical Therapy in Québec, Canada

COS Annual Meeting · June 2023 · Québec, Canada

Saheb H, Harasymowycz P, Matougui K, Beauchemin C, Royer C, Shah-Manek B

Treatment Patterns in Open-Angle Glaucoma Patients Post Initial Diagnosis, Under a Public Insurance Drug Program in Québec, Canada

COS Annual Meeting · June 2023 · Québec, Canada

Mathurin K, Bloom D, Gross JA, Lachaine J

Economic Impact of Clozapine Treatment Persistence: A Canadian Perspective

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) (pp EPH69) · May 2023 · Boston, United States (In-Person Conference)

Guinan K, Mathurin K, Lachaine J

Economic Impact of Rapid Treatment Initiation of HIV with Bictegravir/Emtricitabine/Tenofovir Aladenamide (B/F/TAF) from a Canadian Healthcare Perspective

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) (pp EPH112) · May 2023 · Boston, United States (In-Person Conference)

Patenaude J, Gouault Laliberté A, Beauchemin C, Lachaine J

The Impact of Migraine on Canadians’ Productivity: A Real-World Pharmacy-Based Study

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) (pp PCR72) · May 2023 · Boston, United States (In-Person Conference)

Guinan K, Mathurin K, Lachaine J

Economic Impact of Rapid Treatment Initiation of HIV with Bictegravir/Emtricitabine/Tenofovir Aladenamide (B/F/TAF) from a Canadian Healthcare Perspective

32nd Annual Conference on HIV/AIDS Research (CAHR 2023) · April 2023 · Quebec, Canada – Oral Presentation

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) (pp EPH112), May 2023, Boston, United States (In-Person Conference)

Guinan K, Lachaine J, Paul Roc N, Bull SJ, Tankala D, Barakat S, Hillis CM, Banerji V

The Economic Impact of Treatment Sequencing in the Management of Chronic Lymphocytic Leukemia in Canada Using Venetoclax Plus Obinutuzumab. 64th Annual Meeting and Exposition of the

American Society of Hematology · December 2022 · New Orleans, United States – Présentation Oral

(ASH 2022),

Patenaude J, Gouault Laliberté A, Beauchemin C, Lachaine J

The PROxy Network: A Community Pharmacy-Based Network to Facilitate the Generation of Real-World Evidence

Canadian Association for Population Therapeutics (CAPT) · November 7-9, 2022 · Toronto

Simon J, Ferenczy A, Black D, Royer C, Castonguay A, Marouf R, Beauchemin C

Endometrial Safety, Efficacy and Tolerability of Ospemifene Compared to Current Therapies for the Treatment of Vulvovaginal Atrophy: A Systematic Literature Review and Network Meta-Analysis

The North American Menopause Society (NAMS) · October 2022 · Atlanta, United States

Annual Meeting (pp P78),

Beauchemin C, Dodat F, Au Y, Evans WK, Paulson K, Schuh AC, Storring J, Lachaine J

Evaluating the Economic Burden of Acute Myeloid Leukemia in Canada

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) (pp EE33) · May 2022 · Washington, United States (In-Person and Virtual Conference)

Guinan K, Mathurin K, Au Y, Schuh AC, Bui CN, Chai X, Lachaine J

Venetoclax in Combination with Azacitidine Is Cost-Effective Vs. AZA for the Treatment of Newly Diagnosed Acute Myeloid Leukemia: A Canadian Perspective

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) (pp EE46) · May 2022 · Washington, United States (In-Person and Virtual Conference)

Pratz K, Lachaine J, Suh HS, Li X, Schuh AC, Chai X, Xie J, Yin L, Bui CN

Health State Utilities for Patients with Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) (pp POSB357) · December 2021 · Copenhagen, Denmark (virtual meeting)

Li X, Suh HS, Lachaine J, Schuh AC, Pratz K, Betts KA, Song J, Gu C, Bui CN

Venetoclax Combination Therapies Show Significant Improvements in Overall Survival and Remission in Treatment-Naïve Patients with AML Who Are Ineligible for Intensive Chemotherapy: A Network Meta-Analysis

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) (pp POSC35) · December 2021 · Copenhagen, Denmark (virtual meeting)

Lachaine J, Jain MD, Bibeau J, Marino JP, Ball G

Cost Associated with Implementation of CAR T-Cell Therapy for the Management of Hematologic Cancers in Canada

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) (pp PCN191) · May 2021 · Montreal, Canada (virtual meeting)

Beauchemin C, Guinan K, Mathurin K, Dufresne SF, Rotstein C, Claveau D, Landry L, Lachaine J

Canadian cost-utility analysis of isavuconazole for the treatment of patients with invasive aspergillosis and mucormycosis

Association of Medical Microbiology and Infectious Disease Canada (AMMI Canada) · April 2021 · Oral Presentation (virtual meeting)

Beauchemin C, Guinan, Mathurin K, Dufresne SF, Rotstein C, Claveau D, Landry L, Lachaine J

Canadian cost-utility analysis of isavuconazole for the treatment of patients with invasive aspergillosis and mucormycosis

AMMI Canada · April 2021 · virtual meeting

Hillhouse E, Bibeau J, Parison D, Rahal Y, Lachaine J, Beauchemin C

Economic Impact of an Originator-to-Biosimilar Non-Medical Switch in the Real-World Setting- A Systematic Literature Review

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) (pp PBI8)

Montreal, Canada (virtual meeting)

Mathurin K, Castonguay A, Parison D, Rahal Y, Lachaine J, Beauchemin C

Economic Impact of Originator-to-Biosimilar Non-Medical Switching on Health Care Resource Utilization in Rheumatic Patients in Quebec, Canada

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) (pp PBI10)

Montreal, Canada (virtual meeting)

Schuh AC, Pratz K, Lachaine J, Suh HS, Li X, Chai X, Xie J, Gu C, Bui CN

Projecting the Long-Term Benefits of Venetoclax Combination Therapies for Patients with Newly Diagnosed Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy: An Assessment of Net Health Benefit

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) (pp POSA49)

Copenhagen, Denmark (virtual meeting)

Beauchemin C, Charron JN, Mathurin K, Jobin Gervais K, Barbeau M, Agoumi Y

Cost per Responder Analysis of Latanoprostene Bunod Compared to Prostaglandin Analogs for Open-Angle Glaucoma in Canada

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) (pp PSS5) · 2020 · Milan (virtual meeting)

Nov

Beauchemin C, Guinan K, Mathurin K, Dufresne SF, Rotstein C, Claveau D, Landry L, Lachaine

Isavuconazole for the Treatment of Invasive Aspergillosis and Mucormycosis- A Canadian Cost-Utility Analysis

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) (pp PIN44) · 2020 · Milan (virtual meeting)

Nov

Lachaine J, Charron JN, Gregoire JC, Hegele RA, Leiter LA

Cost-Effectiveness of Icosapent Ethyl (IPE) for the Reduction of the Risk of Ischemic Cardiovascular Events in Canada

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) (pp PCV55) · 2020 · Milan (virtual meeting)

Clinicoecon Outcomes Res. 2023 Apr 20;15:295-308. 10.2147/CEOR.S377935. PMID: 37101608; PMCID: PMC10124620

Patenaude J, Hillhouse E, Aissa F, Filbey S, Lachaine J, Beauchemin C

Economic Evaluation of Biocellulose Wound Dressings for the Management of Chronic Leg Ulcers in Canada

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) · Nov 2-6, 2019 · Copenhagen

Lachaine J, Beauchemin C, Guinan K, Thebault P, Aw A, Banerji V, Fleury I, Owen C

Impact of Oral Targeted Therapy on the Economic Burden of CLL in Canada

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) · Nov 2-6, 2019 · Copenhagen

Guinan K, Beauchemin C, Tremblay J, Hamet P, Chalmer J, Woodward M, Lachaine J

Economic Evaluation of a New Polygenic Risk Score to Prevent Nephropathies in Type-2 Diabetic Patients

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) · Nov 2-6, 2019 · Copenhagen

Stellato D, Thabane M, Beauchemin C, Bornheimer R, Charron JN, Lachaine J, Mathurin K, Delea TE

Cost-Effectiveness Analysis of Dabrafenib Plus Trametinib as Adjuvant Treatment for BRAF V600 Mutation-Positive Melanoma After Surgical Resection in Canada – A Societal Perspective

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) · Nov 2-6, 2019 · Copenhagen

Royer C, Beauchemin C, Lachaine J, Cui A, Jobin Gervais K, Barbeau M

Latanoprostene Bunod for the Treatment of Open-Angle Glaucoma and Ocular Hypertension – Systematic Literature Review and Network Meta-Analysis

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) · May 18-22, 2019 · New Orleans

Mathurin K, Beauchemin C, Lachaine J, Gaudet V, Barbeau M

Cost-effectiveness analysis of eficonazole for the treatment of mild to moderate toenail onychomycosis in Canada

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) (pp PIN33) · May 18-22, 2019 · New Orleans

Beauchemin C, Royer C, Lachaine J, Liu FF, Yim C, Poulin Y

Budget Impact of Use of Apremilast vs. Biologics in the Management of Moderate to Severe Plaque

Psoriasis (PsO) in Quebec, Canada, Using Régie de l’assurance maladie du Québec (RAMQ) · April 14-16, 2019 · Edmonton

Administrative Claims Data. 2019 CADTH Symposium,

Harasymowycz PJ, Royer C, Jobin Gervais K, Cui A, Barbeau M, Lachaine J, Beauchemin C

Effectiveness of Latanoprostene Bunod in Treating OAG and OHT: Network Meta-Analysis

American Academy of Ophthalmology (AAO) · 2019 · San Francisco

Oct. 12-15,

Lachaine J.; Beauchemin C.; Bibeau J.; Patenaude J.; Chokka P.; Proulx J.; Bougie J.K

Canadian economic impact of improved workplace productivity in patients with major depressive disorder treated with vortioxetine. Value in Health. Conference: ISPOR Europe 2018: New Perspectives for Improving 21st Century Health Systems. Spain

21 (Supplement 3) (pp S282) · 2018

Lambert-Obry V.; Lafrance J.; Savoie M.; Lachaine J

Type 2 diabetes mellitus: lack of good practices for real-world evidence studies. Value in Health. Conference: ISPOR Europe 2018: New Perspectives for Improving 21st Century Health Systems. Spain

21 (Supplement 3) (pp S389) · 2018

Lachance S, Bibeau J, Ladjemil N, Lachaine J

Impact of cellular therapy on the economic burden and survival following relapse after HLA identical hematopoietic stem cell transplantation for acute leukemia and myelodysplastic syndrome

In Haematologica · June 2017. Vol. 102, pp. 126-126

Lachaine J, Miron A, Shear N, Alhusayen R, Resource utilization and quality of llife of patients with hidradenitis suppurativa in Canada: results from a population-based survey

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) · May 21-25, 2016 · Washington

Lachaine J, Kouroukis CT

Budget impact analysis for the first-line and second-line treatment of patients with chronic lymphocytic leukemia

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) · May 21-25, 2016 · Washington

Lachaine J, Bitton A, Miron A, Nait

Ladjemil D, The iGenoMed Consortium Literature review of the economic impact of treatments for inflammatory bowel diseases

Canadian Digestive Diseases Week (CDDW) · February 26-29, 2016 · Montreal

Lambert-Obry V, Gouault-Laliberté A, Castonguay A, Zanotti G, Banerjee R, Mates M, Lemieux J, Chabot P, Prady C, Couture F, Lachaine J A Real-World Outcome Research Study on Quality of Life, Work Productivity and Health Care Resource Utilization in Metastatic Breast Cancer for Patients and Caregivers. International Society for Pharmacoeconomics and Outcomes Research (ISPOR), 19th Annual European Congress, 29 October – 2 November, 2016, Vienna, Austria

Gouault-Laliberté A, Bergeron C, Chalifour J-F, Lafond C, Lachaine J Resources Utilization for the Investigation of Pulmonary Nodules in Quebec. International Society for Pharmacoeconomics and Outcomes Research (ISPOR), 19th Annual European Congress, 29 October – 2 November, 2016, Vienna, Austria

Lambert-.‐Obry V, Gouault‐Lalibert A,Castonguay A, Aubin MJ, Vadboncoeur J, Laliberté M-C, Lachaine J Health Care Resource Utilization and Costs Associated With the Management of Non-Infectious Intermediate, Posterior and Panuveitis in Canada. International Society for Pharmacoeconomics and Outcomes Research (ISPOR), 19th Annual European Congress, 29 October – 2 November, 2016, Vienna, Austria

Lachaine J, Larbi M, Melnyk P, Rouleau A, Baribeau V, Stip E Impact of initiation of long-acting injectable antipsychotics on resource utilization in patients with schizophrenia. International Society for Pharmacoeconomics and Outcomes Research (ISPOR), 19th Annual European Congress, 29 October – 2 November, 2016, Vienna, Austria

Lachaine J, Gouault Laliberté A, Miron A, Xenopoulos A Time trade off study for parenteral support in short bowel syndrome in Canada. International Society for Pharmacoeconomics and Outcomes Research (ISPOR), May 21-25, 2016, Washington

Lachaine J, Miron A, Shear N, Alhusayen R The prevalence and incidence of hidradenitis suppurativa in Canada: results from a population-based survey. International Society for Pharmacoeconomics and Outcomes Research (ISPOR), May 21-25, 2016, Washington

Lachaine J, Kouroukis CT Economic evaluation of bendamustine plus rituximab in the first-line treatment of patients with chronic lymphocytic leukemia. International Society for Pharmacoeconomics and Outcomes Research (ISPOR), May 21-25, 2016, Washington

Lachance S, Bibeau J, Lachaine J

Burden of Relapse Following Allogeneic Hematopoietic Stem Cell Transplantation on Health Care Resource Utilization in the Management of Acute Leukemia and Myelodysplastic Syndrome. Blood

128 (22): 2372 · 2016

Lachaine J, Bibeau J, Castonguay A, Barakat S

Cost and resource utilization of uncontrolled and persistent asthma in Canada: a systematic literature review

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) · November 7-11, 2015 · Milan

Lachaine J, Bibeau J, Mathurin K, Miron A, Beauchemin C, Benmouhoub I, Bouchama N, Cadieux-Chalifour S, Castonguay A, Charron JN, Enckle G, Hasani I, Lambert-Obry V, Lapierre ME, Piché-Richard V

Systematic review of economic evaluations in personalized medicine

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) · November 7-11, 2015 · Milan

Lachaine J, Miron A, Nait

Ladjemil D Economic evaluations of treatments for inflammatory bowel diseases

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) · November 7-11, 2015 · Milan

Cyr MC, Bissonnette R, Lachaine J Effects of methotrexate on the risk of myocardial infarction among Canadian patients with psoriasis and psoriatic arthritis

International Conference on Pharmacoepidemiology and Therapeutic Risk Management

August 22-26, 2015 · Boston

Lachaine J, Bibeau J, Castonguay A, Piché-Richard V, Barakat S Systematic review on the correlation between lung function or eosinophil levels and quality of life in asthma. International Society for Pharmacoeconomics and Outcomes Research (ISPOR), November 7-11, 2015, Milan

Lachaine J, Bibeau J, Castonguay A, Piché-Richard V, Barakat S Systematic review on the correlation between lung function or eosinophil levels and health care resource utilization in asthma. International Society for Pharmacoeconomics and Outcomes Research (ISPOR), November 7-11, 2015, Milan

Lachaine J, Lambert-Obry V, Lemay M Literature review of economic evaluations of screening tests for breast cancer. International Society for Pharmacoeconomics and Outcomes Research (ISPOR), November 7-11, 2015, Milan

Beauchemin C, Lapierre ME, Letarte N, Yelle L, Lachaine J How to conduct economic evaluations of new treatments for advanced cancer when overall survival data are not available? Results from a systematic literature review. International Society for Pharmacoeconomics and Outcomes Research (ISPOR), November 7-11, 2015, Milan

Lachaine J, Gaudet D, Miron A, Tremblay K Hospitalizations in hyperchylomicronemia patients in Quebec, Canada; results from a real-world observational study. International Society for Pharmacoeconomics and Outcomes Research (ISPOR), November 7-11, 2015, Milan

Lachaine J, Cyr MC, Mtibaa M, Raymond V, Duong Patient’s adherence to oral anticoagulants in atrial fibrillation. A Canadian Association for Population Therapeutics (CAPT), November 2-3, 2015, Toronto

Lachaine J, Lachance S, Lambert-Obry V, Bibeau J Systematic review of economic evaluations in allogeneic hematopoietic stem cell transplantation. International Society for Pharmacoeconomics and Outcomes Research (ISPOR), May 16-20, 2015, Philadelphia

Lachaine J, Lambert-Obry V, Gaumond S, Desjardins O

Impact of biologics use on depression and anxiety frequency and health care resource utilization in psoriasis: an analysis using the Quebec provincial drug reimbursement program database

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) · Nov 8-12, 2014 · Amsterdam

Gouault-Laliberté A, Bergeron C, Lachaine J

Resources utilization for the investigation of pulmonary nodules in a university hospital center in

Quebec, Canada International Society for Pharmacoeconomics and Outcomes Research (ISPOR) · Nov 8-12, 2014 · Amsterdam

Lachaine J, Lapierre ME, Abdalla N, Rouleau A, Stip E

Treatment patterns of long-acting injectable antipsychotics in the province of

Quebec International College of Neuropsycopharmacology (CINP) · Jun 24-26, 2014 · Vancouver

Lachaine J, Lapierre ME, Beauchemin C, Angyalosi G, Balp MM, Calado F, Debonnett L, Desforges J, Sagkriotis A

Real world evidence on inhaled tobramycin use in CF patients: analysis of the RAMQ data (Canada)

European Cystic Fibrosis Conference (ECFC) · Jun 11-14, 2014 · Gothenburg

Lachaine J, Ben

Amor L, van Stralen J, Sikirica V, Hodgkins P, De G, Yang H, Heroux J Healthcare resource utilization and costs associated with atypical antipsychotics use in children and adolescents with attention deficit/hyperactivity disorder in

Quebec, Canada Canadian Agency for Drugs and Technologies in Health (CADTH) · Jun 6-9, 2014 · Gatineau

Esfahani K, Agulnik JS, Batist G, Brandao G, Tremblay L, Blais N, Kempen LV, Lachaine J, Rousseau C, Cohen V

Biopsy-driven study to identify mechanisms of resistance to crizotinib and to evaluate real-world pharmacoeconomics in advanced

ALK-positive NSCLC patients American Society of Clinical Oncology (ASCO) · Jun 3, 2014 · Chicago

May 30-

Lachaine J, Miron A, Beauchemin C

Economic evaluations of treatments for inflammatory bowel diseases

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) · Jun 1-3, 2014 · Montreal

The iGenoMed Consortium. : a literature review. Canadian Journal of Gastroenterology and Hepatology. 2018; 2018:7439730. 10.1155/2018/7439730

Lachaine J, Lambert-Obry V

Cost-effectiveness of stiripentol in the treatment of severe myoclonic epilepsy in infancy in

Canada International Society for Pharmacoeconomics and Outcomes Research (ISPOR) · Jun 1-3, 2014 · Montreal

Lachaine J, Lapierre ME, Lakhdari K

Chronic obstructive pulmonary disease (COPD) drug utilization: an analysis with the

RAMQ database International Society for Pharmacoeconomics and Outcomes Research (ISPOR) · Jun 1-3, 2014 · Montreal

Lachaine J, Vachon ML, Lambert-Obry V, Beauchemin C

Costs of adverse events associated with treatment of hepatitis C virus infection: an analysis using the Quebec provincial drug reimbursement program database

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) · Jun 1-3, 2014 · Montreal

Lachaine J, Lapierre ME, Abdalla N, Rouleau A, Stip E

Resource use and associated costs of depot antipsychotics: an analysis with the

RAMQ database International Society for Pharmacoeconomics and Outcomes Research (ISPOR) · Jun 1-3, 2014 · Montreal

Lachaine J, Lapierre ME, Abdalla N, Rouleau A, Stip E

Depot antipsychotics treatment patterns: an analysis with the

RAMQ database International Society for Pharmacoeconomics and Outcomes Research (ISPOR) · Jun 1-3, 2014 · Montreal

Lachaine J, Mathurin K, Barakat S

Cost-effectiveness of arsenic trioxide compared with all-trans retinoic acid + idarubicin in the treatment of newly diagnosed acute promyelocytic lymphoma in

Canada International Society for Pharmacoeconomics and Outcomes Research (ISPOR) · Jun 1-3, 2014 · Montreal

Lachaine J, Sikirica V, Mathurin K

Cost-effectiveness of guanfacine extended-release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder in

Canada International Society for Pharmacoeconomics and Outcomes Research (ISPOR) · Jun 1-3, 2014 · Montreal

Lachaine J, Sikirica V, Mathurin K

Cost-effectiveness of guanfacine extended-release as an adjunctive therapy to long-acting stimulants versus long-acting stimulants monotherapy for the treatment of attention-deficit/hyperactivity disorder in

Canada International Society for Pharmacoeconomics and Outcomes Research (ISPOR) · Jun 1-3, 2014 · Montreal

Lachaine J, Baril JP, Lambert-Obry V, Beauchemin C

Comparison of compliance rates and health care resource utilization between antiretroviral treatment (ART) regimens: an analysis using the Quebec provincial drug reimbursement program database

Canadian Conference on HIV/AIDS Research (CAHR) · May 1-4, 2014 · St-John

Lachaine J, Vachon ML, Lambert-Obry V, Beauchemin C

Hepatitis C virus infection treatment patterns and associated costs: an analysis of the Quebec provincial reimbursement program database Canadian Digestive Diseases Week/Canadian Association for the Study of the Liver (CDDW/CASL)

Feb 8-11, 2014 · Toronto

Mathurin K, Beauchemin C, Lachaine J Validation of a global economic model to evaluate the cost-effectiveness of targeted treatments using companion diagnostics in advanced/metastatic cancer treatment using KRAS testing for cetuximab therapy in metastatic colorectal cancer. International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Nov 8-12, 2014, Amsterdam

Mathurin K, Beauchemin C, Lachaine J Development of a global economic model to evaluate the cost-effectiveness of targeted treatments using companion diagnostics in advanced/metastatic cancer treatment. International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Nov 8-12, 2014, Amsterdam

Lachaine J, Lapierre ME, Abdalla N, Rouleau A, Stip E Healthcare costs before and after initiation of long-acting injectable antipsychotics in the province of Quebec. International College of Neuropsycopharmacology (CINP), Jun 24-26, 2014, Vancouver

Lachaine J, Mathurin M, Beauchemin C A proposed global economic model to value companion diagnostics in advanced/metastatic cancer treatment. International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Jun 1-3, 2014, Montreal

Lachaine J, Savoie M, Bibeau J Real-world clinical evidence development: an analysis of relevant international models for the potential implementation of such a program in Quebec. International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Jun 1-3, 2014, Montreal

Lachaine J, Mathurin K, Barakat S Cost-effectiveness of arsenic trioxide in the treatment of relapsed/refractory acute promyelocytic lymphoma in Canada. International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Jun 1-3, 2014, Montreal

Lachaine J, Mathurin K, Barakat S

Cost-effectiveness of arsenic trioxide compared with all-trans retinoic acid + idarubicin in the treatment of newly diagnosed acute promyelocytic lymphoma in

Canada American Society of Hematology (ASH) · Dec 8-10, 2013 · New Orleans

Canada International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Jun 1-3, 2014, Montreal

Lachaine J, Mathurin K, Barakat S

Cost-effectiveness of arsenic trioxide in the treatment of relapsed/refractory acute promyelocytic lymphoma in

Canada American Society of Hematology (ASH) · Dec 8-10, 2013 · New Orleans

Canada. International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Jun 1-3, 2014, Montreal

Sikirica V, van Stralen J, Cloutier M, Ben Amor L, Hodgkins P, Carter V, Guerin A, Lachaine J Treatment patterns in ADHD children/adolescents using atypical antipsychotics in

Quebec Canadian Academy of Child and Adolescent Psychiatry (CACAP) · Nov 17-19, 2013 · Vancouver

Lachaine J, Vachon ML, Lambert-Obry V, Beauchemin C

Hepatitis C virus infection treatment completion: an analysis of the Quebec provincial reimbursement program database

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) · Nov 2-6, 2013 · Dublin

Lachaine J, Vachon ML, Lambert-Obry V, Beauchemin C

Cost associated with adverse events and health care resources utilization in hepatitis C virus infection in

Quebec, Canada International Society for Pharmacoeconomics and Outcomes Research (ISPOR) · Nov 2-6, 2013 · Dublin

Lachaine J, Baril JP, Lambert-Obry V, Beauchemin C

Health care resource utilization and adherence to antiretroviral treatment (ART) by HIV patients: an analysis with the Quebec (Canada) public drug plan database

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) · Nov 2-6, 2013 · Dublin

Lachaine J, Sikirica V, De G, van Stralen J, Ben Amor L, Hodgkins P, Yang H, Heroux J Healthcare resource utilization and costs associated with atypical antipsychotics use in children and adolescents with attention deficit/hyperactivity disorder in

Quebec, Canada International Society for Pharmacoeconomics and Outcomes Research (ISPOR) · Nov 2-6, 2013 · Dublin

Lachaine J, Lapierre ME, Beauchemin C, Balp MM, Calado F, Debonnett L, Desforges J, Sagkriotis A

Tobramycin powder for inhalation for the treatment of cystic fibrosis: analysis of the

RAMQ data International Society for Pharmacoeconomics and Outcomes Research (ISPOR) · Nov 2-6, 2013 · Dublin

Lachaine J, Lambert-Obry V, Dionne PA

Health care resources utilization in Alzheimer’s disease: an analysis with the Quebec provincial drug reimbursement program database

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) · Nov 2-6, 2013 · Dublin

Lachaine J, Vachon ML, Lambert-Obry V, Beauchemin C

Health care resources utilization in hepatitis C virus infection and cost associated with adverse events: an analysis of the Quebec provincial drug reimbursement program database

American Association for the Study of Liver Diseases (AASLD) · Nov 1-5, 2013 · Washington DC

Lachaine J, Beauchemin C

Trends in health care resources utilization, cost and medication selection in the treatment of diabetes

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) · Sep 12-14, 2013 · Buenos Aires

Latin America Congress,

Lachaine J, Baril JP, Beauchemin C, Lambert-Obry V

Compliance to antiretroviral agents (ART) and health care resource utilization by HIV patients: an analysis with the Quebec (Canada) public drug plan database

Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) · Sep 10-13, 2013 · Denver

Lachaine J, Sikirica V, Cloutier M, Ben

Amor L, Hodgkins P, van Stralen J, Carter V, Guerin A Period prevalence of therapy combination and switching among children and adolescents with attention deficit/hyperactivity disorder (ADHD) treated with stimulants in

Canada International Conference on Pharmacoepidemiology (ISPE) · Aug 25-28, 2013 · Montreal

Levesque A, Bissonnette R, Prefontaine S, Lapierre ME, Lachaine J

Relative risk of myocardial infarction for Canadian patients with psoriasis treated systemically as compared to patients treated with phototherapy

International Conference on Pharmacoepidemiology (ISPE) · Aug 25-28, 2013 · Montreal

Levesque A, Bissonnette R, Prefontaine S, Lachaine J

Relative risk of myocardial infarction for Canadian patients with psoriasis treated systemically as compared to patients treated with phototherapy

Canadian Dermatologic Association (CDA) · Jun 27-30, 2013 · Quebec

Ben

Amor L, Sikirica V, De G, Lachaine J, van Stralen J, Heroux J, Yang H, Hodgkins P Therapy combination: a prevalent pattern among children and adolescents with attention deficit/hyperactivity disorder treated with stimulants in the canadian province of

Quebec 4th World Congress on ADHD (WCADHD) · Jun 6-9, 2013 · Milan

Mathurin K, Beauchemin C, Lachaine J

Economic evaluations conducted for assessment of companion tests in cancer therapy: a literature review

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) · May 18-22, 2013 · New Orleans

Mathurin K, Beauchemin C, Lachaine J

The cost-effectiveness of companion tests in cancer therapy: a literature review

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) · May 18-22, 2013 · New Orleans

Lachaine J, Beauchemin C, Mathurin K, Aissa F

Cost-effectiveness of bendamustine in the treatment of rituximab-refractory indolent Non-Hodgkin’s lymphoma in

Canada International Society for Pharmacoeconomics and Outcomes Research (ISPOR) · May 18-22, 2013 · New Orleans

Lachaine J, Beauchemin K, Mathurin K, Aissa F

Cost-effectiveness of bendamustine in the treatment of relapsed indolent Non-Hodgkin’s and mantle cell lymphomas in

Canada International Society for Pharmacoeconomics and Outcomes Research (ISPOR) · May 18-22, 2013 · New Orleans

Lachaine J, Beauchemin C, Lapierre ME, Snow LA

Treatment patterns in pediatric antibiotic formulations: an analysis of the

RAMQ database International Society for Pharmacoeconomics and Outcomes Research (ISPOR) · May 18-22, 2013 · New Orleans

Lachaine J, Beauchemin C, Lapierre ME, Snow LA

Utilization trends of various formulations of testosterone: an analysis of the

RAMQ database International Society for Pharmacoeconomics and Outcomes Research (ISPOR) · May 18-22, 2013 · New Orleans

Lachaine J, Beauchemin C, Lambert-Obry V, Chiva-Razavi S

Economic burden associated with ulcerative colitis in Canada: an analysis using the

RAMQ database International Society for Pharmacoeconomics and Outcomes Research (ISPOR) · May 18-22, 2013 · New Orleans

Lachaine J, Beauchemin C, Desjardins O

Use of anti-TNFα agents in the treatment of psoriasis: an analysis of the

RAMQ database International Society for Pharmacoeconomics and Outcomes Research (ISPOR) · May 18-22, 2013 · New Orleans

Lachaine J, Beauchemin C, Desjardins O

Use of biologic agents in the treatment of rheumatoid arthritis: an analysis of the

RAMQ database International Society for Pharmacoeconomics and Outcomes Research (ISPOR) · May 18-22, 2013 · New Orleans

Lachaine J, Beauchemin C, Chiva-Razavi S

Treatment patterns of adalimumab and infliximab in the treatment of Crohn’s disease over a three-year period: a Canadian assessment

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) · May 18-22, 2013 · New Orleans

Lachaine J, Feagan BG, Martel MJ, Beauchemin C, McHugh K

The impact of TNF inhibitors for Crohn’s disease on health care resource utilization: an analysis using the

RAMQ database Canadian Digestive Disease Week (CDDW) · Mar 1-4, 2013 · Victoria

Lachaine J, Lambert-Obry V, Dionne PA Potential predictors of Alzheimer’s disease: an analysis with the Quebec provincial drug reimbursement program database. International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Nov 2-6, 2013, Dublin

Lachaine J, Moreau A, Beauchemin C, Mathurin K

Economic impact of scoliosis in Canada: a RAMQ database analysis

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) · Nov 3-7, 2012 · Berlin

Lachaine J, Lacroix A, Beauchemin C, Hurry M

Characteristics of patients and treatments in Cushing disease: an analysis based on the

RAMQ database International Society for Pharmacoeconomics and Outcomes Research (ISPOR) · Nov 3-7, 2012 · Berlin

Lachaine J, Serri O, Beauchemin C, Hurry M

Characteristics of patients and treatments in acromegaly: an analysis based on the

RAMQ database International Society for Pharmacoeconomics and Outcomes Research (ISPOR) · Nov 3-7, 2012 · Berlin

Beauchemin C, Johnston JB, Lapierre M, Aissa F, Lachaine J

Relation between progression-free survival and overall survival in chronic lymphocytic leukemia

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) · Nov 3-7, 2012 · Berlin

a literature-based analysis. Current Oncology, 2015;10.3747/co.22.2119

Lachaine J, Beauchemin C, Crochard A, Bineau S

Impact of initiation of treatment with memantine or cholinesterase inhibitors (ChEI) on the use of antipsychotics: analysis of

RAMQ database International Society for Pharmacoeconomics and Outcomes Research (ISPOR) · Nov 3-7, 2012 · Berlin

Lachaine J, Lacroix A, Beauchemin C, Hurry M

Characteristics of patients and treatments in Cushing disease: an analysis based on the

RAMQ database Canadian Society of Endocrinology and Metabolism (CSEM) · Oct 10-13, 2012 · Vancouver

RAMQ database International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Nov 3-7, 2012, Berlin

Beauchemin C, Johnston JB, Lapierre M, Aissa F, Lachaine J

Relation between progression-free survival and overall survival in chronic lymphocytic leukemia

European Society for Medical Oncology (ESMO) · Oct 2, 2012 · Vienna

a literature-based analysis. Current Oncology, 2015;10.3747/co.22.2119

Lachaine J, Yen L, Beauchemin C, Hodgkins P

Factors associated with treatment adherence and persistence in Canadian patients with ulcerative colitis: analysis of the prescription claims from the

RAMQ database International Society for Pharmacoeconomics and Outcomes Research (ISPOR) · Sep 2-4, 2012 · Taipai

Asia-Pacific Congress,

Lachaine J, Beauchemin C, Barbeau M

Cost-effectiveness of asenapine in the treatment of schizophrenia and bipolar disorder in

Canada College International de Neuropharmacologie (CINP) · Jun 3-7, 2012 · Stockholm

Abdalla N, Barbeau M, Lachaine J

Budget impact analysis: do Canadian guidelines meet the needs of public drug plan managers?

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) · Jun 2-6, 2012 · Washington

Lachaine J, Feagan BG, Martel MJ, Beauchemin C, McHugh K

The impact of TNF inhibitors for Crohn’s disease on health care resource utilization: an analysis using the

RAMQ database International Society for Pharmacoeconomics and Outcomes Research (ISPOR) · Jun 2-6, 2012 · Washington

RAMQ database Canadian Digestive Disease Week (CDDW), Mar 1-4, 2013, Victoria

Lachaine J, Beauchemin C, Flavin J

Risk of complications in type II diabetic patients with renal impairment: an analysis of the

RAMQ database International Society for Pharmacoeconomics and Outcomes Research (ISPOR) · Jun 2-6, 2012 · Washington

Lachaine J, Beauchemin C, Flavin J

Health care resources utilization and cost for hypoglycemia and metabolic acidosis in type II diabetes: an analysis of the

RAMQ database International Society for Pharmacoeconomics and Outcomes Research (ISPOR) · Jun 2-6, 2012 · Washington

Lachaine J, Beauchemin C, Mathurin K, Blouin J

Productivity losses associated with vision impairment in

Canada International Society for Pharmacoeconomics and Outcomes Research (ISPOR) · Jun 2-6, 2012 · Washington

Lachaine J, Beauchemin C, Mathurin K, Gilbert D, Beillat M, Corson H

Cost-effectiveness of asenapine in the treatment of bipolar disorder in

Canada International Society for Pharmacoeconomics and Outcomes Research (ISPOR) · Jun 2-6, 2012 · Washington

Lachaine J, Beauchemin C, Mathurin K, Gilbert D, Beillat M, Corson H

Cost-effectiveness of asenapine in the treatment of schizophrenia in

Canada International Society for Pharmacoeconomics and Outcomes Research (ISPOR) · Jun 2-6, 2012 · Washington

Lachaine J

Advanced pharmacoeconomics: the

QALY – pros and cons Canadian Association for Population Therapeutics (CAPT) · May 6-8, 2012 · Montreal

Lachaine J, Beauchemin C, Barbeau M

Tobramycin inhaled solution utilization in cystic fibrosis patients in a

RAMQ database International Society for Pharmacoeconomics and Outcomes Research (ISPOR) · Nov 5-8, 2011 · Madrid

Lachaine J, Beauchemin C, Yen L, Hodgkins P

Economic impact of medication adherence and persistence in the treatment of ulcerative colitis in canada: analyses with the

RAMQ database International Society for Pharmacoeconomics and Outcomes Research (ISPOR) · Nov 5-8, 2011 · Madrid

Lachaine J, Beauchemin C, Martel MJ

Comorbidities associated with biologics treated diseases

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) · Nov 5-8, 2011 · Madrid

Lachaine J, Beauchemin C, Crochard A, Bineau S

Impact of initiation of treatment with memantine or cholinesterase inhibitors (ChEI) on the use of psychotropic drugs: analysis of

RAMQ database Clinical Trial in Alzheimer’s Disease (CTAD) · Nov 3-5, 2011 · San Diego

Touchon J, Lachaine J, Beauchemin C, Crochard A, Rive B, Bineau S

Memantine delays the admission of Alzheimer’s disease patients to nursing home: cost-effectiveness analysis in

France Clinical Trial in Alzheimer’s Disease (CTAD) · Nov 3-5, 2011 · San Diego

Lachaine J, Yen L, Beauchemin C, Hodgkins P

Determinants of adherence and persistence in the treatment of ulcerative colitis in

Canada: analyses with the RAMQ database United European Gastroenterology Week (UEGW) · Oct 22-26, 2011 · Stockholm

Lachaine J, Beauchemin C, Amer R

Economic evaluation of dexmedetomidine for sedation in the intensive care

Canadian Society for Hospital Pharmacists (CSHP) · Aug 6-10, 2011 · Vancouver

Lachaine J, Beauchemin C

Economic evaluation of dexmedetomidine for sedation in the intensive care

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) · May 21-25, 2011 · Baltimore

Amer R Canadian Society for Hospital Pharmacists (CSHP), Aug 6-10, 2011, Vancouver

Lachaine J, Beauchemin C, Martel MJ, Goyette A

Dose variation with adalimumab and infliximab in the treatment of Crohn disease: a Canadian assessment

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) · May 21-25, 2011 · Baltimore

Lachaine J, Beauchemin C, Martel MJ, Goyette A Health care resources utilization in the management of juvenile idiopathic arthritis

Analyses with the

RAMQ database International Society for Pharmacoeconomics and Outcomes Research (ISPOR) · May 21-25, 2011 · Baltimore

RAMQ Database European Congress of Rheumatology (EULAR), May 25-26, 2011, Londres

Lachaine J, Beauchemin C, Martel MJ, Goyette A

Dose variation with adalimumab and infliximab in the treatment of

Crohn disease: a Canadian assessment Canadian Digestive Disease Week (CDDW) · Mar 1, 2011 · Vancouver

Crohn disease: a Canadian assessment International Society for Pharmacoeconomics and Outcomes Research (ISPOR), May 21-25, 2011, Baltimore

Lachaine J, Beauchemin C, Martel MJ, Goyette A

Dose variation with adalimumab and infliximab in the treatment of

Crohn disease: a Canadian assessment European Crohn & Colitis Organization (ECCO) · Feb 24-26, 2011 · Dublin

Crohn disease: a Canadian assessment International Society for Pharmacoeconomics and Outcomes Research (ISPOR), May 21-25, 2011, Baltimore

Lachaine J, Beauchemin C Impact of ChEI treatment initiation on psychotropic use. Analyses with the RAMQ database European Federation of Neurological Societies (EFNS), Sep 10-13, 2011, Budapest

Lachaine J, Beauchemin C, Martel MJ, Goyette A Health care resources utilization in the management of juvenile idiopathic arthritis. Analyses with the RAMQ Database European Congress of Rheumatology (EULAR), May 25-26, 2011, Londres

Lachaine J, Beauchemin C, Yen L, Hodgkins P Medication adherence and persistence in the treatment of ulcerative colitis. Analysis with RAMQ data Canadian Digestive Disease Week (CDDW), Feb 26-Mar 1, 2011, Vancouver

Touchon J, Lachaine J, Beauchemin C, Crochard A, Bineau S

Memantine delays the admission of Alzheimer’s disease patients to nursing home: cost-effectiveness analysis in the

French setting International Society for Pharmacoeconomics and Outcomes Research (ISPOR) · Nov 6-9, 2010 · Prague

Lachaine J, Beauchemin C, Yen L, Hodgkins P Medication adherence and persistence in the treatment of ulcerative colitis

Analysis with RAMQ data

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) · Nov 6-9, 2010 · Prague

Canadian Digestive Disease Week (CDDW), Feb 26-Mar 1, 2011, Vancouver

Martel MJ, Ackad N, Lachaine J

Incidence and prevalence of endometriosis in

Quebec International Society for Pharmacoepidemiology (ISPE) · Aug 19-22, 2010 · Brighton

Brault C, Rinfret S, Lachaine J

Cost-utility analysis of anti-smoking treatments

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) · May 15-19, 2010 · Atlanta

Lachaine J, Beauchemin C, Legault M

Economic evaluation of escitalopram to treat major depressive disorder

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) · May 15-19, 2010 · Atlanta

Lachaine J, Beauchemin C, Legault M, Le

Lay A Economic evaluation of the impact of memantine on time to nursing home admission in the treatment of Alzheimer’s disease

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) · May 15-19, 2010 · Atlanta

Lachaine J, Beauchemin C, Hodgkins P, Sasane R Treatment patterns in attention-deficit/hyperactivity disorder

Analyses with the

RAMQ database International Society for Pharmacoeconomics and Outcomes Research (ISPOR) · May 15-19, 2010 · Atlanta

Lachaine J, Beauchemin C, Sasane R, Hodgkins P Adherence and persistence to treatment in patients with attention-deficit/hyperactivity disorder

Analyses with

RAMQ database International Society for Pharmacoeconomics and Outcomes Research (ISPOR) · May 15-19, 2010 · Atlanta

Lachaine J, Beauchemin C, Legault M, Bineau S Impact of memantine treatment initiation on psychotropics use: analyses with the RAMQ database. International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Nov 6-9, 2010, Prague

Lachaine J, Beauchemin C, Ramos E Use of spironolactone to treat congestive heart failure post-myocardial infarction

Analyses with the

RAMQ database International Society for Pharmacoeconomics and Outcomes Research (ISPOR) · Oct 24-27, 2009 · Paris

RAMQ database Canadian Cardiovascular Congress (CCC), Oct 24-28, 2009, Edmonton

Lachaine J, Beauchemin C

Cost-utility analysis of topical diclofenac for the treatment of osteoarthritis of the knee

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) · Oct 24-27, 2009 · Paris

Europe Congress,

Lachaine J, Beauchemin C

Analyse coût-utilité du traitement de l’ostéoarthrite du genou par le diclofénac topique

Réseau québécois de recherche sur l’usage des médicaments (RQRUM) · Jun 2-3, 2009 · Montreal

Lachaine J, Beauchemin C, Ramos E

Utilisation de la spironolactone dans le traitement de l’insuffisance cardiaque

Réseau québécois de recherche sur l’usage des médicaments (RQRUM) · Jun 2-3, 2009 · Montreal

Lachaine J, Beauchemin C, Landry PA

Caractéristiques cliniques et économiques des patients atteints de fibromyalgie

Réseau québécois de recherche sur l’usage des médicaments (RQRUM) · Jun 2-3, 2009 · Montreal

Lachaine J, Beauchemin C, Landry PA

Clinical and economic characteristics of patients with fibromyalgia

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) · May 16-20, 2009 · Orlando

syndrome. Clinical Journal of Pain, 2010 May;26(4):284-90

Lachaine J

Cost-utility analysis of topical diclofenac for the treatment of osteoarthritis of the knee

Canadian Agency for Drugs and Technologies in Health (CADTH) · Apr 5-7, 2009 · Ottawa

Beauchemin C International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Europe Congress, Oct 24-27, 2009, Paris

Lachaine J, Martel MJ, Poulin YP, Langley R

Health care resources utilisation by patients with psoriasis

American Academy of Dermatology (AAD) · Mar 6-10, 2009 · San Francisco

Lachaine J, Beauchemin C, Ramos E Use of spironolactone to treat congestive heart failure post-myocardial infarction. Analyses with the RAMQ database Canadian Cardiovascular Congress (CCC), Oct 24-28, 2009, Edmonton

Lachaine J, Beauchemin C, Ramos E Use of spironolactone to treat congestive heart failure post-myocardial infarction. Analyses with the RAMQ database International Society for Pharmacoepidemiology (ISPE), Aug 16-19, 2009, Providence

Rinfret S, Kennedy W, Lachaine J, Lemay A, Rodés-Cabau J, Olivier F, Bertrand O

The Economic impact of same-day discharge after transradial percutaneous coronary intervention and a single bolus of abciximab; an analysis from the EASY trial American Heart Association

Nov 9-11, 2008 · New Orleans

Lachaine J, Martel MJ, Poulin YP, Langley R

Health care resources utilisation by patients with psoriasis

International Society for Pharmacoepidemiology (ISPE) · Aug 16-21, 2008 · Copenhagen

American Academy of Dermatology (AAD), Mar 6-10, 2009, San Francisco

Lachaine J, Martel MJ, Poulin YP, Langley R

Health care resources utilisation by patients with psoriasis

Canadian Association for Population Therapeutics (CAPT) · Aug 1, 2008 · Quebec

American Academy of Dermatology (AAD), Mar 6-10, 2009, San Francisco

Lachaine J, Lescrauwaet B, Sauriol L

Health care resources consumption in type-2 diabetes management

Canadian Diabetes Association (CDA) · Oct 18-21, 2006 · Toronto

Lachaine J, Lescrauwaet B, Sauriol L

Treatment patterns in type-2 diabetes management

Canadian Association for Population Therapeutics (CAPT) · May 10-13, 2006 · Toronto

Canadian Diabetes Association (CDA), Oct 18-21, 2006, Toronto

Lachaine J, Lescrauwaet B, Sauriol L

Health care resources consumption in type-2 diabetes management

Canadian Association for Population Therapeutics (CAPT) · May 10-13, 2006 · Toronto

Canadian Diabetes Association (CDA), Oct 18-21, 2006, Toronto

Lachaine J, Lescrauwaet B, Sauriol L Treatment patterns in type-2 diabetes management Canadian Diabetes Association (CDA), Oct 18-21, 2006, Toronto

Dobson R, Henry C, Taylor J, Zello G, Lachaine J

The health care team: what role do community pharmacists see for themselves?

Canadian Pharmacists Association (CPHA) · May 29-31, 2005 · Quebec

Lachaine J, Tarride JE

Painful neuropathic disorders, an analysis of the

RAMQ database Canadian Pain Society (CPS) · May 11-14, 2005 · Halifax

Lachaine J, Tarride JE

Painful neuropathic disorders: an analysis of the Régie de l’assurance maladie du Québec (RAMQ) database

Canadian Association for Population Therapeutics (CAPT) · Apr 17-19, 2005 · Vancouver

Lachaine J, Zlateva G, Charbonneau C

Treatment patterns and health care resources utilisation by patients with asthma and

COPD Canadian Association for Population Therapeutics (CAPT) · Apr 17-19, 2005 · Vancouver

Lachaine J, Merickle E, Montpetit M A model of assessing the cost-effectiveness of atorvastatin and simvastatin in achieving Canadian

Working Group Guidelines Canadian Association for Population Therapeutics (CAPT) · Apr 17-19, 2005 · Vancouver

Lachaine J, Tarride JE Resource utilization in diabetic painful neuropathy patients. An analysis of the RAMQ database Canadian Pain Society (CPS), May 11-14, 2005, Halifax

Lachaine J, Tarride JE

Persistence and adherence to cholesterol lowering agents: evidences from

RAMQ data Canadian Association for Population Therapeutics (CAPT) · 2004 · Winnipeg

Jun,

Lachaine J, Ali F, Merikle E

Persistence and adherence to antihypertensive agents

Canadian Association for Population Therapeutics (CAPT) · 2004 · Winnipeg

Jun,

Lachaine J, Yelle L, Kaiser L, Dufour A, Hopkins S, Deuson R

Quality of life and economic impacts of chemotherapy induced nausea and vomiting in the context of current practice in Canada MASCC/ISOO

Jun · 2004 · Miami

Lachaine J, Ali F, Merikle E

Persistence and adherence to antihypertensive agents

American Society of Hypertension (ASH) · 2004 · New-York

Canadian Association for Population Therapeutics (CAPT), Jun, 2004, Winnipeg

Lachaine J, Tarride JE

Persistence and adherence to cholesterol lowering agents: evidences from

RAMQ data Canadian Association for Population Therapeutics (CAPT) · Apr 1, 2003 · Quebec

Jun, 2004, Winnipeg

Lachaine J, Yelle L, Kaizer L, Dufour A, Desjardins B, Desjardins B, Deuson R

Burden of chemotherapy-induced nausea and vomiting in the context of current

Canadian practice European Organization for Research and Treatment of Cancer (EORTC) · 2003 · Bruxelles

Lachaine J, Yelle L, Kfaizer L, Dufour A, Desjardins B, Desjardins B, Deuson R

Incidence and burden of chemotherapy-induced nausea and vomiting in the context of current practice in

Ontario and Quebec (Canada) American Society of Clinical Oncology (ASCO) · 2003